Want to see HK:2552 full AI Analyst Report?
2552 Stock Chart & Stats
HK$2.36
-HK$0.02(-0.79%)
At close: 4:00 PM EDT
HK$2.36
-HK$0.02(-0.79%)
Day’s Range― - ―
52-Week RangeHK$1.97 - HK$3.94
Previous CloseN/A
Volume865.87K
Average Volume (3M)815.13K
Market Cap
HK$2.11B
Enterprise ValueHK$1.29B
Total Cash (Recent Filing)HK$1.07B
Total Debt (Recent Filing)HK$354.20M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding1,056,605,000
10 Day Avg. Volume601,450
30 Day Avg. Volume815,133
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.71
Price to Sales (P/S)5.69
P/FCF Ratio-45.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.52Price Target Upside49.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)HK$1.06B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRapid 2025 revenue expansion indicates stronger commercial traction for dorzagliatin and growing demand in the company’s diabetes franchise. If maintained, this top-line momentum can broaden market penetration, improve operating leverage, and support greater reinvestment in the product pipeline.
Improved Gross MarginThe substantial gross-margin improvement points to better product economics and more value retained from each sale. Sustained margin expansion would strengthen the economics of commercialization, create greater capacity to absorb research and selling costs, and improve the path toward eventual profitability.
Manageable LeverageManageable leverage and restored positive equity provide a more stable financial base for continuing commercialization and development activities. Broadly stable total debt also limits balance-sheet deterioration, preserving flexibility compared with the negative-equity position reported in 2024.
Bears Say
Negative Cash GenerationNegative operating and free cash flow show that reported business performance is not currently translating into internally generated funding. Persistent cash burn could require greater use of financial resources or external funding, reducing flexibility to expand commercialization and advance pipeline programs.
Ongoing Operating LossesDespite strong revenue growth and better gross margin, the core business remains materially loss-making at the operating and EBITDA levels. This indicates that selling, development, and other operating expenses still outweigh gross profit, leaving the company without sustainable operating profitability.
Volatile Earnings QualityThe sharp disconnect between strongly positive net income and continuing operating losses makes reported earnings less predictable and less representative of recurring business performance. This weakens confidence in profit durability and complicates assessment of when the underlying franchise can become sustainably profitable.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$1.97 and its highest was HK$3.94 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$2.11B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 152 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Aug 20, 2026. The company reported -HK$0.035 earnings per share for the quarter.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Undervalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of -HK$0.035 in its last earnings report. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
2552 Company Deck
2552 Earnings Call
Q2 2026
0:00 / 0:00
2552 Stock 12 Month Forecast
Average Price Target
HK$3.52
▲(49.15% Upside)
Technical Analysis
HUTCHMED (China)
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―